Free tool
FAERS Monitor: Truxima
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761088 or its brand name (Truxima, Rituximab-Abbs). Reports on generic versions are filed under their own applications.
Reports
5,105
Serious
3,752
73% of reports
Hospitalization
1,394
Death reported
537
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use2,347
- intentional product use issue347
- hypertension295
- pain272
- rheumatoid arthritis264
- fatigue261
- infusion related reaction251
- intentional dose omission248
- dyspnoea246
- pyrexia242
- rash234
- drug ineffective232
- nausea225
- headache216
- death208
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 4 |
| 2018 | 91 |
| 2019 | 342 |
| 2020 | 556 |
| 2021 | 820 |
| 2022 | 1,093 |
| 2023 | 749 |
| 2024 | 598 |
| 2025 | 527 |
| 2026 | 325 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,054 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intentional dose omissionSignal | 248 | 36.1 | 32.0 | 8,378 |
| intentional product use issueSignal | 347 | 16.4 | 14.8 | 4,997 |
| infusion related reactionSignal | 251 | 15.7 | 13.9 | 3,427 |
| off label useSignal | 2,347 | 11.1 | 10.7 | 22,363 |
| rheumatoid arthritisSignal | 264 | 9.6 | 8.5 | 2,032 |
| hypertensionSignal | 295 | 5.7 | 5.1 | 1,162 |
| pyrexiaSignal | 242 | 2.9 | 2.5 | 300 |
| rashSignal | 234 | 2.2 | 2.0 | 157 |
| pain | 272 | 1.8 | 1.6 | 104 |
| dyspnoea | 246 | 1.8 | 1.6 | 87 |
| headache | 216 | 1.4 | 1.2 | 27 |
| fatigue | 261 | 1.4 | 1.2 | 28 |
| nausea | 225 | 1.2 | 1.0 | 6 |
| death | 208 | 1.0 | 0.9 | 0 |
| drug ineffective | 232 | 0.7 | 0.6 | 25 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.